{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-101816","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-09-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.637300+00:00","generated_at":"2026-05-31T02:25:54.839714+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039","bullets":["Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.","Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.","Settlement subject to review by U.S. DOJ and FTC as required by law.","Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-101816","json":"https://secwatch.observer/filing/0001104659-24-101816.json","markdown":"https://secwatch.observer/filing/0001104659-24-101816.md","text":"https://secwatch.observer/filing/0001104659-24-101816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/0001104659-24-101816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/tm2424315d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:25:54.839714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}